



# Accolade Inc.

## Investor Presentation

April 2023

NASDAQ: ACCD



This presentation contains “forward-looking statements” –that is, statements related to future, not past, events. In this context, forward-looking statements often address our expected future business and financial performance and financial condition, and often contain words such “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “guidance,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or similar expressions. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. For us, particular uncertainties that could cause our actual results to be materially different than those expressed in our forward-looking statements include: our ability to achieve or maintain profitability; our reliance on a limited number of customers for a substantial portion of our revenue; our expectations and management of future growth; our market opportunity and our ability to estimate the size of our target market; the effects of increased competition as well as innovations by new and existing competitors in our market; and our ability to retain our existing customers and to increase our number of customers. Important risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) changes in laws and regulations applicable to our business model; (ii) changes in market or industry conditions, regulatory environment and receptivity to our technology and services; (iii) results of litigation or a security incident; (iv) the loss of one or more key customers or partners; (v) the impact of COVID-19 on our business and results of operation; and (vi) changes to our abilities to recruit and retain qualified team members. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our Annual Report on Form 10-K for the fiscal year ended February 28, 2023 and subsequent reports that we file.

This presentation includes non-GAAP financial measures. These non-GAAP financial measures are in addition to, and not a substitute for or superior to measures of financial performance prepared in accordance with GAAP. There are a number of limitations related to the use of these non-GAAP financial measures. For example, other companies may calculate similarly-titled non-GAAP financial measures differently. Refer to the Appendix for a reconciliation of these non-GAAP financial measures to the most directly comparable GAAP measures.



# The Cost of a Poor Healthcare Experience


**76%**  
of people don't understand their available benefits or how they work




**88%**  
of workers reported extreme stress, compared to 16% before the onset of COVID



**\$225.88B**  
in lost workforce productivity due to poor healthcare and preventable chronic conditions cost U.S. companies in 2020



**56%**  
of people say healthcare coverage was a deciding factor in leaving their job




# An imperfect system

The healthcare system is **reactive**

Healthcare access is **inadequate**


Investments alone **aren't improving**  
the experience



75%

of healthcare spending  
is on chronic health  
conditions\*


\* cdc.gov



80%

of the US lacks adequate  
access to healthcare\*

\* goodrx.com



\$29B

in digital health startup  
investment in 2021, more  
than 3X the 2019 level\*

\* Rock Health



# Accolade is Engineered to Care

Predictive  
Engagement



Proactive  
Care




Addressing  
Barriers



# Engineered to Care

Technology and People deliver



# The People Behind Our Solutions

## Top Physicians & Medical Experts

---

- From the top 50 U.S. medical schools
- Average experience of 15 years
- 900+ specialists and experts



## Registered Nurses

---

- Varied experience across medical disciplines
- Average experience of 16 years



## Health Assistants

---

- 66% degreed professionals
- Benefits and claims experts



## Extended Care Team

---

- Claims and Benefits Specialist, Logistics Support, Medical Records Collection



# The three pillars of Engineered to Care

## Predictive Engagement

---

Going beyond standard engagement strategies to drive the right action

## Proactive Care

---

Personalized recommendations and interventions delivered by Clinical Experts

## Addressing Barriers

---

Identify and resolve barriers so members get the right care



# Engineered to Care: Predictive Engagement

Going beyond standard engagement strategies to drive the right action



## Intercept


Combine verification of benefits & utilization management with members insights to inform engagement approach

## Outbound

Identify 50% more high-risk members earlier in the care journey

## Inbound

High-risk members connect directly to a nurse



**70%+**  
family engagement

**95%+**  
high-cost engagement

# Engineered to Care: Proactive Care

Personalized recommendations and interventions delivered by Clinical Experts



**66%**  
of members  
engage before  
seeking care

Member Data + Possible Clinical Interventions =

## True Health Actions™

Rank what is most impactful for each member according to their situation and need.

Ranked Interventions



1. Find PCP
2. MSK Program
3. Referral to EAP



# Engineered to Care: Addressing Barriers

Identify and resolve barriers so members get the care they need

## What We Do

- Listen with empathy
- Understand context
- Identify barriers to care

## Accolade Impact

- Good access to care
- Improved health literacy
- Confidence in care decisions




**3x**

more likely  
to uncover  
contextual  
factors that  
doctors miss




# Delivering Value Across the Entire Healthcare Journey

## Benefits Education, Utilization and Engagement



## Provider Selection, Care Delivery and Support



# A Truly Powerful, Personalized Healthcare Platform

Personal | Data Driven | Value Based

## Accolade Advocacy

---

Personalized, trusted guidance and education for all benefits and clinical needs

## Accolade Expert MD

---

Real-time expert consultations for members facing high impact conditions

## Accolade Care


---

Same-day access to virtual primary and mental healthcare to address needs holistically



# Achieving Better Outcomes


What we know shapes what we do




# Personalized Healthcare

Engagement cannot be solved with any single approach

## ACCOLADE ENGAGEMENT MODEL



# Our Engagement and Clinical Approach Drives Results



# Personalized Healthcare Impact

TRUE HEALTH ENGINE

**60+%**  
engagement

**69%**  
repeat engagement

TRUE HEALTH ACTION PLAN

**93%**  
of members follow recommended action

**91%**  
of members state Accolade understands their care needs and saves time

**4.7%**  
lower claims costs – independent validation (Aon)

**98%**  
of members state having Accolade positively impacts how they view their employers



# Engaging the Ecosystem

Accolade helps members learn about and leverage the benefits available to them. Driving appropriate utilization of these programs is core to our value proposition.



**Customers' Carriers (representative)**

A collection of logos for various health carriers, including Meritain Health (An Aetna Company), Aetna, Cigna, UnitedHealthcare, Humana, UMR (A UnitedHealthcare Company), Kaiser Permanente, AmeriBen, and PriorityHealth.

**Trusted Partner Ecosystem**

A collection of logos for various trusted partner ecosystem companies, including Carrot, RxSS (Rx Savings Solutions), Headspace Health, FOLX, Lyra, Virta, Carrum Health, Hinge Health, Brightside, Vivante Health, Wellright, and Jellyvision.

**Ecosystem Programs (representative)**

A collection of logos for various ecosystem programs, including Rethink, MeQuilibrium, Progyny (Smarter Fertility Benefits), Business Solver, CompSych (The GuidanceResources Company), Express Scripts, VSP (Vision care for life), LabCorp (Laboratory Corporation of America), Optum, WebMD, Delta Dental, CVS Caremark, Benefit Harbor, Sedgwick, Mercer, Plansource, Crossover Health, Virgin Pulse, Fidelity Investments, ExtraTrade, Bright Horizons, WageWorks, Limeade, MetLife, Magellan Health, Premise Health, and Allstate.

# Accelerating Accolade's Innovation

Continuous investment in clinical transformation and operational excellence





IPO • July 2020

Follow-on • October 2020

Convertible • March 2021



# Significantly Expanded Addressable Market



# Compelling Growth Strategy

<b>Grow customer base</b>	Further penetrate our market of 30,000+ self- and fully insured employers
<b>Retain and expand customer relationships</b>	Grow relationships especially through the sale of add-on services such as Virtual Primary Care and Expert Medical Opinion
<b>Continue to innovate</b>	Leverage machine learning, predictive analytics, and multimodal communication to generate efficiencies and better outcomes, while introducing new solutions – Accolade Care, Accolade Expert MD and Accolade One
<b>Grow into adjacent markets</b>	Our evolution into Accolade’s new category of Personalized Healthcare opens the door to new opportunities, especially with government-sponsored healthcare plans, such as TRICARE, Medicare, Medicaid
<b>Expand partnerships</b>	Establish partnerships with health plans and other healthcare innovators that complement our solutions and extend capabilities and/or improve distribution
<b>Pursue strategic M&amp;A</b>	Capitalize on Accolade’s position as a natural platform for consolidation given our strategic relationships with employers, member engagement model, open technology architecture, and scale

# Financials



# Financial Highlights


## Growing Customer, Solution and Channel Diversification

Strong sales momentum and expansion of product suite supporting broader market capture




## ARR Bookings & new offerings driving substantial revenue growth

33% ARR growth FY22 to FY23; Ended FY23 with \$309mm ACV



## PMPM recurring revenue model provides significant revenue visibility

Multi-year contracts with base + performance-based PMPM fees; strong customer retention



## Adjusted Gross Margin expansion provides path to profitability

Delivering Cost of Revenue improvements via tech-driven efficiencies


Higher margin product offerings and ecosystem partners leverage tech platform



## Investments in Sales & Marketing and Product & Tech driving market expansion



Building out enterprise and mid-market salesforce to complement strategic segment

Secure, open technology platform supports innovation including new offerings and add-ons



# Strong Revenue Growth

Predictable, highly visible, and recurring revenue




\*Revenue CAGR is pro forma to account for acquisitions in FY 2022  
 \*\* GDR in FY 23 = 96% excluding the impact of a large customer loss




# Annual Result Trends


## Revenue




## Adjusted Gross Profit and Adjusted Gross Profit Margin



## Adjusted EBITDA (Loss)\* (as % of revenue)



## Adjusted Operating Expenses as a % of Revenue\*




\*Please refer to page 29 for important information regarding non-GAAP financial measures



# Revenue and Customer Growth + Unit Economics Drive Path to Profitability

Revenue vs Adjusted EBITDA (Loss) as a % of Revenue\*



Annual Contract Value	\$122 M	\$161 M	\$211 M	\$286 M	\$309 M+
Gross Dollar Retention	95%	99%	99%	98%	87%+

\*Please refer to page 29 for important information regarding non-GAAP financial measures

\*\*20% revenue growth excludes impact from terminated large customer in FY23

+ Excluding the impact of terminated large customer, FY23 ACV growth was 20% and GDR was 96%

# Financial Targets and Goals (Non-GAAP)


		Long-Term Goals	Commentary
Adj. Gross Margin		50–55%	Investments in technology and offering mix projected to drive GM% up
Adj. Operating Expenses	P&T as % of Rev.	13–17%	Projecting to continue to increase absolute dollar investments in Product & Tech at a decreasing rate
	S&M as % of Rev.	15–20%	As sales efficiency metrics continue to indicate investments yield attractive returns and revenue growth, expect to invest at 15–20% of revenues. As growth moderates, reduction in S&M is a lever to drive profitability
	G&A as % of Rev.	7–9%	Projecting to increase absolute dollar spend in G&A with growth, with % of revenues declining below 10% at scale
Adj. EBITDA Margin		15–20%	Expecting to drive 15–20% Adj. EBITDA margin at scale

*\*Please refer to page 29 for important information regarding non-GAAP financial measures*





# Appendix



# Reconciliations of Revenue to Adjusted Gross Profit & Net loss to Adjusted EBITDA

Adjusted Gross Profit is a non-GAAP financial measure that we define as revenue less cost of revenue, excluding depreciation and amortization, and excluding stock-based compensation and severance costs. We define Adjusted Gross Margin as our Adjusted Gross Profit divided by our revenue. We believe Adjusted Gross Profit and Adjusted Gross Margin are useful to investors, as they eliminate the impact of certain noncash expenses and allow a direct comparison of these measures between periods without the impact of noncash expenses and certain other nonrecurring operating expenses.

Adjusted EBITDA is a non-GAAP financial measure that we define as net loss adjusted to exclude interest expense (income), net, income tax expense (benefit), depreciation and amortization, stock-based compensation, acquisition and integration-related costs, goodwill impairment, change in fair value of contingent consideration, severance costs, and other expense (income). Severance costs include severance payments related to the realignment of our resources. Other expense (income) includes foreign exchange gain or loss. We believe Adjusted EBITDA provides investors with useful information on period-to-period performance as evaluated by management and comparison with our past financial performance. We believe Adjusted EBITDA is useful in evaluating our operating performance compared to that of other companies in our industry, as this measure generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance.

Adjusted Gross Profit, Adjusted Gross Margin and Adjusted EBITDA have certain limitations, including that they exclude the impact of certain non-cash charges, such as depreciation and amortization, whereas underlying assets may need to be replaced and result in cash capital expenditures, and stock-based compensation expense, which is a recurring charge. These non-GAAP financial measures may also not be comparable to similarly titled measures of other companies because they may not calculate such measures in the same manner, limiting their usefulness as comparative measures. In evaluating these non-GAAP financial measures, you should be aware that in the future we expect to incur expenses similar to the adjustments in this presentation. Our presentation of non-GAAP financial measures should not be construed as an inference that our future results will be unaffected by these expenses or any unusual or nonrecurring items. When evaluating our performance, you should consider these non-GAAP financial measures alongside other financial performance measures, including the most directly comparable GAAP measures set forth in the reconciliation tables below and our other GAAP results.

**The following tables present, for the periods indicated, reconciliation of our revenue to Adjusted Gross Profit and net loss to Adjusted EBITDA.**



# Adjusted EBITDA (Loss) Reconciliation

(\$ in thousands)

Fiscal year ended February 28 (29),	2019	2020	2021	2022	2023
Net Loss	\$ (56,496)	\$ (51,365)	\$ (50,652)	\$ (123,124)	\$ (459,650)
Adjusted for:					
Interest expense (income), net	2,374	2,925	3,724	2,905	(255)
Income tax expense (benefit)	55	129	4	(5,639)	(3,624)
Depreciation and amortization	9,391	8,516	8,212	42,608	46,377
Stock-based compensation	5,721	6,002	9,576	72,939	72,644
Acquisition & integration-related costs	--	567	2,050	13,219	1,218
Goodwill impairment					299,705
Change in fair value of contingent consideration	--	--	--	(45,416)	--
Severance costs					7,065
Other expense	90	107	147	133	15
<b>Adjusted EBITDA (Loss)</b>	<b>\$ (38,865)</b>	<b>\$ (33,119)</b>	<b>\$ (26,939)</b>	<b>\$ (42,375)</b>	<b>\$ (36,505)</b>

\*Please refer to page 29 for important information regarding non-GAAP financial measures



# Adjusted Gross Margin Reconciliation

(\$ in thousands)

Fiscal year ended February 28 (29),	2019	2020	2021	2022	2023
Revenue	\$ 94,811	\$ 132,507	\$ 170,358	\$ 310,021	\$ 363,142
Less:					
Cost of revenue, excluding depreciation and amortization	(60,568)	(73,685)	(93,673)	(169,019)	(198,905)
Gross Profit, excluding depreciation and amortization	34,243	58,822	76,685	141,002	164,237
Add:					
Stock-based compensation, cost of revenue	255	318	948	3,197	4,794
Severance costs, costs of revenue					1,025
<b>Adjusted Gross Profit</b>	<b>\$ 34,498</b>	<b>\$ 59,140</b>	<b>\$ 77,633</b>	<b>\$ 144,199</b>	<b>170,056</b>
Gross Margin, excluding depreciation and amortization	36.1%	44.4%	45.0%	45.5%	45.2%
<b>Adjusted Gross Margin</b>	<b>36.4%</b>	<b>44.6%</b>	<b>45.6%</b>	<b>46.5%</b>	<b>46.8%</b>

\*Please refer to page 29 for important information regarding non-GAAP financial measures



# Adjusted Operating Expense Reconciliation

(\$ in thousands)

Fiscal year ended February 28 (29),	2019	2020	2021	2022	2023
Revenue	\$ 94,811	\$ 132,507	\$ 170,358	\$ 310,021	\$ 363,142
Operating Expenses	88,220	107,026	123,462	266,727	627,751
Less:					
Depreciation and amortization	(9,391)	(8,516)	(8,212)	(42,608)	(46,377)
Stock-based compensation	(5,466)	(5,684)	(8,628)	(69,742)	( 67,850)
Acquisition, integration-related costs and other	--	(567)	(2,050)	(13,219)	(1,218)
Goodwill Impairment	--	--	--	--	(299,705)
Change in fair value of contingent consideration	--	--	--	45,416	--
Severance costs					(6,040)
<b>Adjusted Operating Expenses</b>	<b>\$ 73,363</b>	<b>\$ 92,259</b>	<b>\$ 104,572</b>	<b>\$ 186,574</b>	<b>\$ 206,561</b>
<b>Adjusted Operating Expenses as a % of Revenue</b>	<b>77%</b>	<b>70%</b>	<b>61%</b>	<b>60%</b>	<b>57%</b>

\*Please refer to page 29 for important information regarding non-GAAP financial measures





**Accolade**  
PERSONALIZED HEALTHCARE